AGA guidelines recommend testing for Lynch syndrome in all patients with colorectal cancer
the ONA take:
The American Gastroenterological Association has published a new guideline for colorectal cancer (CRC). The guideline, published in Gastroenterology, recommends all patients with a new diagnosis of CRC should undergo testing for Lynch syndrome.
Lynch syndrome is an inherited disorder in which the MMR gene is mutated, making the body less able to fix errors in the DNA. The syndrome is the most common inherited cause of colorectal cancer, affecting approximately 700,000 Americans. Children have an approximately 50% chance of inheriting the disorder. Most people with the syndrome are not aware that they have it.
Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 30% of persons who develop CRC have a family history of the disease, and 5% to 6% have mutations diagnostic of a known hereditary cancer syndrome. Persons with Lynch syndrome have an 80% higher risk for colorectal cancer and a 60% higher risk for endometrial cancer.
AGA recommends all patients with colorectal cancer get tested for Lynch syndrome
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|